## Clinical Trials and Cohort Studies Grants Outcomes 2022: Factsheet



# Clinical Trials and Cohort Studies (CTCS) Grants 2022 Outcomes Factsheet

#### **CTCS Grants**

- The objective of the CTCS Grant scheme is to support high-quality clinical trials and cohort studies that address important gaps in knowledge, leading to relevant and implementable findings for the benefit of human health.
- The expected outcomes of the CTCS Grant scheme are improvements in health and well-being, health care practice or policy, as a result of:
  - high-quality clinical trials that provide reliable evidence of the effects of health-related interventions on health outcomes (or appropriate surrogates),
  - high-quality cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes, and/or
  - high quality retrospective cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes.
- Neither the application budget nor the number of applications that a CIA could submit was capped for the CTCS Grant scheme.
- The CTCS Grant scheme has a funding allocation from the Medical Research Endowment Account (MREA) of \$75 million (which includes \$5 million for structural priority funding).
- The total amount of funding requested from NHMRC by applicants to the CTCS Grant scheme was approximately \$574.5 million.

#### **CTCS Grant Outcomes**

- 28 applications from institutions across the country will be funded.
- The ratio of clinical trials to cohort studies applications was approximately 2:1.
- The ratio of clinical trials to cohort studies grants was exactly 4:3.

Total number of applications received	243
Total number of applications applying for NHMRC funding	241
Number of grants awarded	28
Percentage of applications awarded	11.6%
Total amount awarded	\$72,897,049.10
Mean budget for awarded grants	\$2,603,466.04

### Outcomes by Trial or Study Type

• Applications were allocated to a Grant Review Panel (GRP) primarily based on the applicant's nominated peer review areas.

Trial or Study Type*	Applications	Grants awarded	Funded rate	Proportion of grants awarded	Total Value
Clinical Trials	166	16	9.6%	57.1%	\$45,162,191.55
Cohort Studies	75	12	16.0%	42.9%	\$27,734,857.55

<sup>\*</sup>As determined by the peer review area selected by the applicants.

### Outcomes by Broad Research Area (BRA)

- NHMRC is committed to supporting a broad range of research from discovery science through to clinical research (including clinical trials), health services and public health research.
- Clinical Medicine and Science received the greatest allocation of CTCS funding, with Health Services and Public Health BRAs also funded.

Broad Research Area	Applications	Grants Awarded	Funded Rate (%)	Proportion of Grants Awarded	Total Value
Basic Science	1	0	0.0	0.0	N/A
Clinical Medicine and Science	170	15	8.8%	53.6%	\$43,903,734.77
Health Services Research	20	2	10.0%	7.1%	\$4,329,898.40
Public Health	50	11	22%	39.3%	\$24,663,415.93

#### Funded Rates by Gender

• Funded rates for both female and male lead Chief Investigators (CIAs) were equal for the CTCS Grant scheme.

CIA Gender	Applications	Grants Awarded	Funded Rate (%)	Proportion of grants awarded
Female	120	14	11.7	50
Male	121	14	11.6	50
Not Stated	0	N/A	N/A	N/A

### Aboriginal and Torres Strait Islander Health Research and Researchers

- NHMRC is committed to allocating at least five per cent of the MREA each year to research directed at improving the health of Aboriginal and Torres Strait Islander peoples.
- Applications that address Aboriginal and Torres Strait Islander health represent 14.3% of the awarded grants and 16.3% of the CTCS Grant funding awarded.

Indigenous Identified/Indigenous Focused	Applications	Grants Awarded	Funded Rate (%)	Proportion of grants awarded
Aboriginal and Torres Strait Islander Focused Research	10	4	40.0%	14.3%
Applications with one or more researchers of Aboriginal and/or Torres Strait Islander descent in their teams	13	5	38.5%	17.9%

Note: There is overlap between the rows above due to applications that address Aboriginal and Torres Strait Islander health from researchers who are of Aboriginal and/or Torres Strait Islander descent.

#### In conclusion

• The fourth year of funding in this scheme has resulted in 28 applications being supported, with an overall funded rate of 11.6%.